Cited by 102Mast cells and histamineGastrointestinal Tumor Research and TreatmentHistiocytic Disorders and Treatments

Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis

Open access
Álvarez-Twose, Iván, Jara-Acevedo, María, Morgado, José Mário, García-Montero, Andrés, Sánchez-Muñoz, Laura, Teodósio, Cristina, Matito, Almudena, Mayado, Andrea +4 more·2016·Journal of Allergy and Clinical Immunology

Abstract

Background Well-differentiated systemic mastocytosis (WDSM) is a rare variant of systemic mastocytosis (SM) characterized by bone marrow (BM) infiltration by mature-appearing mast cells (MCs) often lacking exon 17 KIT mutations. Because of its rarity, the clinical and biological features of WDSM remain poorly defined. Objective We sought to determine the clinical, biological, and molecular features of a cohort of 33 patients with mastocytosis in the skin in association with BM infiltration by well-differentiated MCs and to establish potential diagnostic criteria for WDSM. Methods Thirty-three patients with mastocytosis in the skin plus BM aggregates of round, fully granulated MCs lacking strong CD25 and CD2 expression in association with clonal MC features were studied. Results Our cohort of patients showed female predominance (female/male ratio, 4:1) and childhood onset of the disease (91%) with frequent familial aggregation (39%). Skin involvement was heterogeneous, including maculopapular (82%), nodular (6%), and diffuse cutaneous (12%) mastocytosis. KIT mutations were detected in only 10 (30%) of 33 patients, including the KIT D816V (n = 5), K509I (n = 3), N819Y (n = 1), and I817V (n = 1) mutations. BM MCs displayed a unique immunophenotypic pattern consisting of increased light scatter features, overexpression of cytoplasmic carboxypeptidase, and aberrant expression of CD30, together with absent (79%) or low (21%) positivity for CD25, CD2, or both. Despite only 9 (27%) of 33 patients fulfilling the World Health Organization criteria for SM, our findings allowed us to establish the systemic nature of the disease, which fit with the definition of WDSM. Conclusions WDSM represents a rare clinically and molecularly heterogeneous variant of SM that requires unique diagnostic criteria to avoid a misdiagnosis of cutaneous mastocytosis per current World Health Organization criteria.

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2015.05.008

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Álvarez-Twose, I., Jara-Acevedo, M., Morgado, J. M., García-Montero, A., Sánchez-Muñoz, L., Teodósio, C., Matito, A., Mayado, A., Caldas, C., Mollejo, M., Orfao, A., & Escribano, L.
Affiliations
  • Hospital Virgen del Valle (ES)
  • Universidad de Salamanca (ES)
  • Hospital Virgen de la Salud (ES)
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2016-01
Volume
137
Issue
1
Pages
168-178.e1
ISSN
0091-6749 (ISSN-L)
OpenAlex
W593231466
Cited by
102
References
4
Citations by year
2026: 4 · 2025: 12 · 2024: 8 · 2023: 17 · 2022: 12 · 2021: 12 · 2020: 10 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 4 · 2015: 3
FWCI
3.44
Type
journal article
Language
en
Open access
Locations
  • Journal of Allergy and Clinical Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Funders
  • Asociación Española de Mastocitosis (AEDM 2014)
  • Instituto de Salud Carlos III
  • FEDER
  • Ministry of Economy and Competitivity (PI11/02399)
  • Fundación Ramón Areces (CIVP16A1806)
  • Novartis Farmacéutica
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
  • Health Sciences › Medicine › Physiology › Histiocytic Disorders and Treatments
Keywords
systemic mastocytosis, KIT mutations, KIT D816V, bone marrow mastocytosis, CD30, CD25, CD2, carboxypeptidase, diagnostic criteria, familial aggregation, pediatric onset
MeSH terms
Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Male, Mast Cells, Middle Aged, Mutation, Skin, Immunophenotyping, Proto-Oncogene Proteins c-kit, Mastocytosis, Cutaneous, Mastocytosis, Systemic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review